summary
Introduced
10/11/2019
10/11/2019
In Committee
10/14/2019
10/14/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To amend the 21st Century Cures Act to reauthorize funding for FDA innovation projects, and for other purposes. 1
AI Summary
This bill aims to reauthorize and extend funding for various innovation and safety initiatives at the Food and Drug Administration (FDA) under the 21st Century Cures Act. The key provisions include: extending the availability of direct spending savings for FDA innovation projects until 2029; allocating funds for modernizing the FDA's technical infrastructure, supporting continuous manufacturing of drugs and biological products, advancing the development of individualized gene therapy products, enhancing inspections and enforcement activities, improving customs and border technologies, advancing postmarket surveillance systems, and supporting the development of non-opioid alternatives. The bill also extends the annual reporting requirement and the sunset date for these FDA funding provisions until 2029.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (2)
Last Action
Referred to the Subcommittee on Health. (on 10/14/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/4633/all-info |
| BillText | https://www.congress.gov/116/bills/hr4633/BILLS-116hr4633ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr4633/BILLS-116hr4633ih.pdf.pdf |
Loading...